Page last updated: 2024-09-03

imatinib mesylate and Synovioma

imatinib mesylate has been researched along with Synovioma in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baker, LH; Verweij, J	1
Antonescu, CR; Barbashina, V; Ho, AL; Ladanyi, M; Laé, M; Saito, T; Schwartz, GK; Vasudeva, SD	1
Kwan, W; Liu, S; Lubieniecka, JM; Nielsen, TO; Terry, J	1
Adamson, PC; Bernstein, ML; Blaney, SM; Bond, M; Krailo, M; Pappo, A; Schultz, KR	1

Reviews

1 review(s) available for imatinib mesylate and Synovioma

Article	Year
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Cytotoxins; Dermatofibrosarcoma; Disease Progression; Gastrointestinal Stromal Tumors; Hemangioendothelioma; Hemangiosarcoma; Humans; Imatinib Mesylate; Leiomyosarcoma; Liposarcoma, Myxoid; Piperazines; Pyrimidines; Research Design; Sarcoma; Sarcoma, Synovial; Skin Neoplasms	2010

Article

Year

Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.

European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:5

Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Cytotoxins; Dermatofibrosarcoma; Disease Progression; Gastrointestinal Stromal Tumors; Hemangioendothelioma; Hemangiosarcoma; Humans; Imatinib Mesylate; Leiomyosarcoma; Liposarcoma, Myxoid; Piperazines; Pyrimidines; Research Design; Sarcoma; Sarcoma, Synovial; Skin Neoplasms

2010

Trials

1 trial(s) available for imatinib mesylate and Synovioma

Article	Year
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatric blood & cancer, 2008, Volume: 50, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial	2008

Article

Year

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.

Pediatric blood & cancer, 2008, Volume: 50, Issue:2

Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial

2008

Other Studies

2 other study(ies) available for imatinib mesylate and Synovioma

Article	Year
PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer research, 2012, Sep-01, Volume: 72, Issue:17 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mechanistic Target of Rapamycin Complex 1; Mice; Molecular Targeted Therapy; Multiprotein Complexes; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma, Synovial; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription, Genetic	2012
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab	2005

Article

Year

PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.

Cancer research, 2012, Sep-01, Volume: 72, Issue:17

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mechanistic Target of Rapamycin Complex 1; Mice; Molecular Targeted Therapy; Multiprotein Complexes; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma, Synovial; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription, Genetic

2012

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab

2005